Clinical trials: Chronic Graft Versus Host Disease
- Condition Chronic Graft Versus Host Disease
- Age group Children (under 18)
- Accepts healthy volunteers yes
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Graft-versus-host-disease
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
- Trial name
- NCT03640481
- Testing
- Belumosudil (KD025)
- Where
- 35 sites in United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Chronic Graft vs Host Disease
Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Chronic graft-versus-host disease (cGVHD) can be hard to diagnose, difficult to manage and contributes significantly to morbidity and mortality in hematopoietic stem cell transplantation patients.
- Trial name
- ABLE-cGVHD (NCT02067832)
- Where
- 25 sites in United States, Austria and 1 more
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Chronic Graft vs Host Disease
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
- Trial name
- GVHD-TReG (NCT03683498)
- Testing
- Regulatory T-cell enriched infusion
- Where
- Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla